A novel inhibitor of the insulin/IGF signaling pathway protects from age-onset, neurodegeneration-linked proteotoxicity

Authors

  • Tayir El-Ami,

    1. Department of Biochemistry and Molecular Biology, The Institute for Medical Research Israel – Canada (IMRIC), The Hebrew University School of Medicine, Jerusalem, Israel
    Search for more papers by this author
    • These authors contributed equally to this work.
  • Lorna Moll,

    1. Department of Biochemistry and Molecular Biology, The Institute for Medical Research Israel – Canada (IMRIC), The Hebrew University School of Medicine, Jerusalem, Israel
    Search for more papers by this author
    • These authors contributed equally to this work.
  • Filipa Carvalhal Marques,

    1. Department of Biochemistry and Molecular Biology, The Institute for Medical Research Israel – Canada (IMRIC), The Hebrew University School of Medicine, Jerusalem, Israel
    2. Faculty of Medicine, Center of Ophthalmology and Vision Sciences (COCV), Institute for Biomedical Research in Light and Image (IBILI), University of Coimbra, Coimbra, Portugal
    Search for more papers by this author
  • Yuli Volovik,

    1. Department of Biochemistry and Molecular Biology, The Institute for Medical Research Israel – Canada (IMRIC), The Hebrew University School of Medicine, Jerusalem, Israel
    Search for more papers by this author
  • Hadas Reuveni,

    Corresponding author
    1. NovoTyr Therapeutics Ltd., Tel Hai, Israel
    • Correspondence

      Ehud Cohen, Department of Biochemistry and Molecular Biology, the Institute for Medical Research Israel – Canada (IMRIC), the Hebrew University School of Medicine, Jerusalem 91120, Israel. Tel.: +972-2-6757328; fax: +972-2-6757326;

      e-mail: ehudc@ekmd.huji.ac.il or

      Hadas Reuveni, NovoTyr Therapeutics Ltd., Tel Hai, Israel. Tel.: +972-54-2666041; fax: +972-2-5337020;

      e-mail: hadas.reuveni@gmail.com

    Search for more papers by this author
  • Ehud Cohen

    Corresponding author
    1. Department of Biochemistry and Molecular Biology, The Institute for Medical Research Israel – Canada (IMRIC), The Hebrew University School of Medicine, Jerusalem, Israel
    • Correspondence

      Ehud Cohen, Department of Biochemistry and Molecular Biology, the Institute for Medical Research Israel – Canada (IMRIC), the Hebrew University School of Medicine, Jerusalem 91120, Israel. Tel.: +972-2-6757328; fax: +972-2-6757326;

      e-mail: ehudc@ekmd.huji.ac.il or

      Hadas Reuveni, NovoTyr Therapeutics Ltd., Tel Hai, Israel. Tel.: +972-54-2666041; fax: +972-2-5337020;

      e-mail: hadas.reuveni@gmail.com

    Search for more papers by this author

Summary

Aging manipulation is an emerging strategy aimed to postpone the manifestation of late-onset neurodegenerative disorders such as Alzheimer's (AD) and Huntington's diseases (HD) and to slow their progression once emerged. Reducing the activity of the insulin/IGF signaling cascade (IIS), a prominent aging-regulating pathway, protects worms from proteotoxicity of various aggregative proteins, including the AD-associated peptide, Aβ- and the HD-linked peptide, polyQ40. Similarly, IGF1 signaling reduction protects mice from AD-like disease. These discoveries suggest that IIS inhibitors can serve as new drugs for the treatment of neurodegenerative maladies including AD and HD. Here, we report that NT219, a novel IIS inhibitor, mediates a long-lasting, highly efficient inhibition of this signaling cascade by a dual mechanism; it reduces the autophosphorylation of the IGF1 receptor and directs the insulin receptor substrates 1 and 2 (IRS 1/2) for degradation. NT219 treatment promotes stress resistance and protects nematodes from AD- and HD-associated proteotoxicity without affecting lifespan. Our discoveries strengthen the theme that IIS inhibition has a therapeutic potential as a cure for neurodegenerative maladies and point at NT219 as a promising compound for the treatment of these disorders through a selective manipulation of aging.

Ancillary